热门资讯> 正文
生物GAAP每股收益攀升-0.31美元
2025-05-14 21:53
- Climb Bio press release (NASDAQ:CLYM): Q1 GAAP EPS of -$0.31.
- Cash Position: Cash, cash equivalents and marketable securities were $197.8 million as of March 31, 2025. Cash, cash equivalents and marketable securities are expected to fund operations through 2027.
More on Climb Bio
- Seeking Alpha’s Quant Rating on Climb Bio
- Historical earnings data for Climb Bio
- Financial information for Climb Bio
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
